OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair
- 88 Downloads
Radiotherapy is becoming one major therapeutics for non-small cell lung cancer (NSCLC). Identifying novel radiosensitizers will greatly increase the efficacy of radiotherapy and benefit more patients. OTU deubiquitinase 4 (OTUD4) has been reported involved in DNA damage repair pathways and could be a potential target for chemotherapy therapy. This study aimed to investigate the roles of OTUD4 in regulation of radiosensitivity of NSCLC via modulating DNA repair.
The expression of OTUD4, γ-H2Ax and ATM/CHK2/p53 pathway-related signaling molecules were detected by Western blotting and QRT-PCR. The methylation of OTUD4 promoter was investigated by 5-aza-deoxycytidine treatment, methylation-specific PCR and bisulfite genomic sequencing assays. Radiosensitivity was assessed by the clonogenic formation assay. Cell cycle, cell apoptosis were analyzed by flow cytometry. DNA damage and repair were determined by comet assay, γ-H2Ax foci staining and flow cytometry.
OTUD4 is dramatically downregulated in NSCLC and its downregulation significantly correlates with poor prognosis of NSCLC patients. Promoter hypermethylation is responsible for the loss of OTUD4 expression in NSCLC cells. Overexpression of OTUD4 increases radiosensitivity of NSCLC cells exhibiting as impaired clonogenic formation ability, enhanced cell cycle arrest and increased cell apoptosis. Moreover, molecular mechanism study reveals that OTUD4 radiosensitizs NSCLC cells via ATM/CHK2/P53 signaling and inhibiting homology-directed repair of DNA double strand breaks induced by ionizing radiation.
This study uncovers a tumor-suppressing role of OTUD4 and that OTUD4 is a potential radiosensitizer for NSCLC.
KeywordsNon-small cell lung cancer Radiosensitizer OTUD4 Homology repair DNA methylation
non-small cell lung cancer
lung squamous cell carcinoma
OTU deubiquitinase 4
progression free survival
post progression survival
DNA double strand breaks
gene set enrichment analysis
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer related death, with an estimated over 1.8 million new cases and 1.5 million deaths world widely in 2012 . Non-small cell lung cancer (NSCLC) is the main histological type of lung cancer, which accounts for nearly 85% of all cases of lung cancer . Thus, it is a big challenge to fight against NSCLC. Radiotherapy is becoming more and more important for treatment of NSCLC. Recent years, radiotherapy, especially stereotactic body radiotherapy (SBRT), achieved promising benefit for NSCLC patients . However, radioresistance hinders further improving efficacy of radiotherapy and results in treatment failure in patients. Therefore, elucidating the mechanism of radioresistance and finding/developing effective radiosensitizer are very important.
The primary effect of ionizing radiation (IR) is bringing damages to cellular DNA directly and indirectly . Upon DNA damage, ATM is quickly recruited to the DSBs sites in an MRE11-RAD50-NBS1 (MRN) complex dependent way, and subsequently activated via autophosphorylation . The histone variant H2AX is phosphorylated by activated ATM at serine 139 residue. Phosphorylated H2AX (termed γ-H2AX) then incorporates into nucleosomes instead of the core histone at the DNA damage sites, which can spread about 2 megabases of chromatin region or thousands of nucleosomes and formed nuclear foci when stained with specific antibody . γ-H2AX recognizing antibodies have become a gold standard for detecting the presence of DSBs [7, 8]. In addition to H2AX, activated ATM phosphorylates lots of other proteins involved in DNA damage response (DDR) and repair signaling pathways, such as cell cycle check point, DNA repair, apoptosis, and so forth.
DNA double strand breaks (DSBs) are considered the most cytotoxic type of DNA lesion induced by IR. Homologous recombination (HR) repair is important for DSBs precise repair. Modulating factors that are essential for HR affects sensitivity to ionizing radiation [9, 10]. OTUD4 has been reported to take part in DNA damage repair pathways including GG-NER and alkylation damage repair pathway [11, 12]. Moreover, knockdown of OTUD4 significantly increased the sensitivity of PC-3 and H23 tumor cells to methyl methanesulfonate, an alkylating agent which leads to DNA alkylation damage . Hence, OTUD4 could be a potential target for cancer therapy via regulating DNA damage repair. However, whether OTUD4 participates in DSBs repair, especially HR, and modulates radiosensitivity of cancer cells remain to be elucidated.
In this study, we find that OTUD4 is significantly downregulated in NSCLC cell lines and patient specimens. Promoter methylation accounts for the depression of OTUD4 in NSCLC. Decreased expression of OTUD4 significantly correlates with poor prognosis of NSCLC patients. Moreover, overexpression of OTUD4 could increase radiosensitivity as evidenced by impaired clonogenic formation ability, increased cell cycle arrest and enhanced cell death after ionizing radiation treatment. Further investigation proved that OTUD4 inhibit DSBs homology repair (HR). Together, this study implicates that OTUD4 is a potential radiosensitizer for NSCLC.
Materials and methods
Patient tissue specimens
Patient consent and approval from the Institutional Research Ethics Committee of Tianjin Cancer Institute and Hospital were obtained for the use of the clinical materials for research purposes. Ten primary NSCLC tumor and adjacent non-tumor tissue sample pairs were obtained from the Department of Pathology, Tianjin Medical University Cancer Hospital. Fresh tumor tissues were snap-frozen in liquid nitrogen in the operating room and then stored at − 80 °C. The tumor tissues were histopathologically and clinically diagnosed using both fresh and formalin-fixed, paraffin-embedded tumor tissues. All fresh samples were confirmed by hematoxylin and eosin (H&E) staining in frozen sections for the histopathological analysis.
Non-small cell lung cancer cell lines, including A549, H292, H460, H520, H1299, H1975 and PC-9, were cultured in RPMI 1640 medium (Gibco, Rockville, MD, USA). 293FT cells were cultured in DMEM medium (Gibco). DR-GFP-U2OS and EJ5-U2OS cell line [13, 14] were shared by Prof. Lei Shi’s laboratory at Tianjin Medical University and cultured in DMEM medium. The medium were supplemented with 10% FBS, 1% Non-essential amino acids, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco). Lung bronchus epithelial cell line BEAS-2B was cultured in BEGM medium (Lonza).
Plasmids, transfection and stable cell line construction
OTUD4 was PCR amplified from cDNA of BEAS-2B cells with C-terminus flag-tagged and subcloned into the BamH I/SpeI sites of pSin-EF2-puro vector and validated by sequencing. Plasmids pSin-EF2-OTUD4, psPAX2 and pMD2.G were cotransfected into 293FT cells with Lipofectamine-2000 (Invitrogen) for virus package. Twenty-four and 48 h later, the virus-containing medium were collected, filtered and infected H460 and A549 cells daily. The infected cells were then selected with medium containing puromycin (1 μg/ml, Sigma) for at least 1 week and further maintained at medium containing low concentration of puromycin (0.5 μg/ml).
Western blotting and antibodies
Western blotting was conducted as previously reported . The following antibodies were used: OTUD4 (#ABN477) was form Millipore; γ-H2AX (#9718), p-CHK2 (#2661), p53 (#2524), p21 (#2947), p-ATM (#5883) and Caspase-3 (#9662) were form Cell Signaling Technology; ATM (A1106) and α-tubulin (T9026) were from Sigma-Aldrich; CHK2 (sc-17747) and GAPDH (sc-365062) were from Santa Cruz Biotechnology.
RNA extraction, reverse transcription (RT) and real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen). cDNA was synthesized using M-MLV Reverse Transcriptase (Promega). FastStart Universal SYBR Green Master (Roche) was used for quantitative real-time PCR. Amplification and real-time analysis was performed with BioRad CFX96 system (BioRad). Primers were as following: OTUD4, forward 5′-AGACCCGAACCAAGCACAT-3′, and reverse 5′-CTGGCTTTTGTTCCGCA-3′; GAPDH, forward 5′-GAAGGTGAAGGTCGGAGT CA-3′, and reverse 5′-TTGAGGTCAATGAAGGGGTC-3′. Transcript levels were normalized to the housekeeping gene GAPDH levels. The relative mRNA levels were calculated according to the comparative Ct (ΔΔCt) method, where Ct represents the threshold cycle for each transcript.
Methylation specific PCR
Methylation specific PCR (MSP) was performed according to a previous study . Briefly, Genomic DNA was extracted using TIANamp Genomic DNA Kit (TIANGEN). 2 μg of genomic DNA was bisulfite-treated with EpiTect Bisulfite Kit (Qiagen). Bisulphite-treated DNA was amplified using primers specific for either methylated or unmethylated DNA. The sequences of methylated-specific (M) primer and unmethylated-specific (U) primer for OTUD4 were: OTUD4 (M), forward 5′-CGTTACGGTTCGGAATAGGTAC-3′, reverse 5′-ACATAAAAACTACCGTCGA CGTC-3′; OTUD4 (U), forward 5′-TTGTTATGGTTTGGAATAGGTATGA-3′, reverse 5′-CAACATAAAAACTACCATCAACATC-3′.
Bisulfite genomic sequencing
Genomic DNA from different cells and patients’ tumor tissues were bisulfite-treated with the Epitect Bisulfite Kit (Qiagen). Bisulfite-treated DNA was amplified with bisulfite-sequencing PCR (BSP) primers located in the OTUD4 promoter. The primers sequences were: forward, 5′-AGGGTTAGTTTTATATGGTTAGGT-3′, reverse, 5′-ACCTAAATCCTAAATCAAACAAC-3′. PCR products were purified and ligated into pMD19-T Vector System (Takara). Plasmids from single colonies were extracted and sequenced. At least 3 clones of each sample were selected for sequencing.
Cell clonogenic formation assay
The cell clonogenic formation assay was performed according to a previous report . Briefly, cells were trypsinized and suspended. Then 200, 300, 1000, 5000, or 10000 H460 cells or 200, 300, 400, 1000 and 4000 A549 cells were seeded into 6-well cell culture plates in triplicates respectively. After attaching to the plates (6 to 8 h), the cells were treated with single-dose irradiation (0, 2, 4, 6, or 8 Gy). After incubated for about 2 weeks, cultures were fixed with pechiled methanol and stained with 0.1% crystal violet. The number of colonies with > 50 cells was counted under a dissecting microscope. The percentage of cell survival was calculated. The experiment conducted at least three times.
Cell cycle analysis
Cells were irradiated with 6 Gy dosage and allowed to recover for 12 h. Cells were fixed, stained with PI, and analyzed by flow cytometry as previous reported . Thirty thousand cells were analyzed by using a FACS alibur instrument (BD Biosciences). The cell cycle distribution was assessed using ModFit LT 3.1 trial cell cycle analysis software. Representative images from three independent experiments are shown.
Single-cell gel electrophoresis (comet) assay
Cells were irradiated and allowed to recover for 3 h prior to analysis. The single cell comet assays were carried using CometAssay Kit (4250-050-K, Trevigen) following the manufacturer’s instructions. DNA damage was quantified for at least 50 cells for each experimental condition by determining percent of DNA in the tail relative to the total DNA using the software Open Comet_ImageJ.
Cells were trypsinized and seeded on coverslips (Thermo Fisher Scientific, Lafayette, CO) in 24-well plate overnight. The next day cells were irradiated with single dose and allowed to recover for indicated time prior to analysis. Immunostaining was performed according to a previous report . Anti-γH2AX (#9718, 1:200; Cell signaling Technology), anti-Rad51 (ab63801, Abcam) and species-specific FITC-conjugated secondary antibodies (1:500; Invitrogen) were used. Gray level images were acquired under a laser scanning microscope (Axio Imager.Z2, Carl Zeiss Co. Ltd.). Images were captured using the AxioVision Rel.4.6 computerized image analysis system. At least 50 cells were counted for quantification of γ-H2AX foci.
Homologous recombination reporter assay
4 × 10^5 DR-GFP-U2OS or EJ5-U2OS cells were seeded into 6-cm plates. Next day, 2 μg of pCMV-I-SceI  and 2 μg of pSin-EF2-OTUD4 or vector plasmid were cotransfected into cells using Lipofectamin-2000 (Invitrogen). Forty-eight hours later, GFP-positive cells was quantitated by flow cytometric analysis (FACS Calibur; BD Biosciences). Representative images from three independent experiments are shown.
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Softare Inc.). Unless indicated otherwise, all results were presented as mean ± SD. Two-tailed, unpaired student’s t test was used for comparisons between groups for statistical significance. p < 0.05 in all cases was considered statistically significant.
OTUD4 is downregulated in lung cancer and its downregulation associated with poor prognosis of patients with lung cancer
Hypermethylation in the promoter region accounts for depression of OTUD4
OTUD4 radiosensitizes NSCLC cells
Overexpression of OTUD4 promotes G2/M cell cycle arrest and apoptosis
OTUD4 inhibits homology-directed DNA repair
DSBs is the main cause of cell death induced by IR. HR and non-homologous end joining (NHEJ) are the two major ways to repair DSBs. Next, the effect of OTUD4 on HR and NHEJ DNA repair signaling was evaluated using DR-GFP U2OS and EJ5-U2OS reporter cells respectively [13, 14]. With these reporters, DSBs are introduced into the chromosome by expressing the I-SceI endonuclease (Fig. 5c and Additional file 3: Fig. S3C, E, F), and, if DSBs repaired, GFP is then expressed and subsequently quantified by flow cytometry. As shown, overexpression of OTUD4 resulted in a significant reduction of the percentage of GFP-positive cells in the DR-GFP U2OS but not that in the EJ5-U2OS reporter cells (Fig. 5d, Additional file 3: Fig. S3D), which indicated that OTUD4 inhibited DNA repair via HR signaling. Moreover, Rad51 staining confirmed that OTUD4 inhibited HR in NSCLC cells as indicated by less Rad51 foci in OTUD4 overexpressing cells after IR treatment (Fig. 5e, f).
A previous study reported that OTUD4 homozygous mutation was found in patients with ataxia and hypogonadotropic hypogonadism. Knockdown of otud4 in zebrafish embryos induced defects in the eye, optic tectum, and cerebellum . Up to date, this is the only report about deregulated OTUD4 in a pathological condition. Here, we report for the first time that deregulated OTUD4 associate with NSCLC. In this study, we found that OTUD4 was significantly downregulated in NSCLC cell lines and tumor tissues compared with normal controls (Fig. 1a–f). Analysis form Kaplan–Meier Plotter (http://kmplot.com) proves that the expression of OTUD4 positively correlates with the prognosis of NSCLC patients. Patients with lower OTUD4 expression show significantly shorter time of OS, FPS and PPS (Fig. 1g–i). These results indicate a tumor-suppressing role of OTUD4 the NSCLC.
OTUD4 has been reported to play multiple roles in DNA damage repair. Abigail Lubin and colleagues identified OTUD4 as a binding partner of XPC and modulating the ubiquitination of XPC . XPC is an important positive regulator of NER [23, 24], thus they proposed that OTUD4 involved in NER. However, because ubiquitination of XPC had been proved both positively and negatively regulating NER [25, 26, 27], which might result from different type chain linkages of ubiquitination at different lysine residues, the exact role of OTUD4 in NER is not clear. By systematically analyzing, Yu Zhao et al. demonstrated that the OTUD4 could complex with USP7-USP9X. They proved that the OTUD4-USP7-USP9X complex was required for alkylation damage resistance and repair via promoting stability of ALKBH3, a demethylases for alkylation damage repair . In our study, we find that OTUD4 could radiosensitize NSCLC cells by inhibiting the HR DNA repair signaling (Figs. 3 and 5), which broadened the role of OTUD4 in DNA damage repair.
OTUD4 was originally identified as a K48-specific deubiquitinase . Very recently, Nima Mosammaparast et al.  proved that OTUD4 could switch to a K63-specific deubiquitinase upon phosphorylated near its catalytic domain. Numerous evidence have proved that ubiquitinase and deubiquitinase play important roles in DNA damage repair signaling transduction [30, 31]. According to a previous report, knockdown of OTUD4 increased the ubiquitination of XPC, which suggests the deubiquitinase activity of OTUD4 might be essential for NER . Here, we show that OTUD4 inhibits HR repair (Fig. 5d, e). Yet, whether the deubiquitinase activity of OTUD4 involves in HR repair and what the exact mechanism is unexplored. Because K63 polyubiquitination plays pivotal roles in HR repair , we propose a hypothesis that OTUD4 might be phosphorylated by ATM and thus function as a K63-specific deubiquitinase to inhibit DSBs HR repair. Indeed, a SQ-rich region (aa334-aa458), which is characterized as the motif phosphorylated by ATM [33, 34, 35], is present in OTUD4 (data not shown). Nevertheless, Nima Mosammaparast et al. demonstrated that OTUD4 promotes alkylation damage repair by promoting stability of ALKBH3, which is independent on the deubiquitinase activity of OTUD4, but instead depends on the deubiquitinase activity of its interactors, USP7 and USP9X. Thus, OTUD4 might also function as an adapter and modulates HR repair signaling via other interactors. However, more investigations are needed to validate and uncover the underlying mechanisms.
Overall, in this study, we show that OTUD4 is silenced by promoter methylation and its downregulation correlates with poor prognosis in NSCLC. Overexpression of OTUD4 impairs DSBs HR repair, enhances cell cycle arrest and increases cell death induced that by IR. Our results suggest a tumor-suppressing function of OTUD4 and prove OTUD4 to be a potential target for radiosensitizing NSCLC.
In conclusion, our data suggested that OTUD4 was downregulated in tissues and cells of NSCLC resulted from promoter hypermethylation. Downregulated OTUD4 correlated with poor prognosis of NSCLC patients. Ectopic overexpression of OTUD4 radiosensitized NSCLC cells via inhibiting HR repair of DSBs induced by IR, which further led to impaired clonogenic formation, enhanced cell apoptosis and cell cycle arrest. Collectively, this study showed that OTUD4 was a potential novel therapeutic target against NSCLC.
WZQ designed the study, prepared, edited and reviewed the manuscript. QMH, GY, ZJL, LZ, and WH performed experimental studies. MMB and YZY did literature research, gave comments and reviewed the manuscript. MZY designed the study and wrote the manuscript. All authors read and approved the final manuscript.
We would like to thank Prof. Lei Shi and Yupeng Chen (Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Tianjin Medical University) for sharing DR-GFP-U2OS and EJ5-U2OS cells.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Consent for publication
All authors approved the publication of this manuscript.
Ethical approval and consent to participate
All procedures in this study that involved human participants were performed in accordance with the 1964 Helsinki declaration and its later amendments. The protocol was approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital. Informed consent was obtained from all individual participants included in the study. Furthermore, the care and use of laboratory animals was in accordance with the principles and standards set forth in the Principles for Use of Animals (National Guide for Grants and Contracts).
This work was supported by the National Natural Science Foundation of China (Grant Nos. 31700144, 81502660, 81472797 and 81872465), Natural Science Foundation of Tianjin Municipal Science and Technology Commission (Grant Nos. 16JCQNJC10000 and 17JCQNJC10600), and the Foundation of Tianjin Medical University (Grant No. 2015KYZQ09).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.